Enzymotec (ENZY) Misses Q2 EPS by 4c; Trims FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enzymotec Ltd. Reports Second Quarter 2016 Unaudited Financial Results
August 9, 2016 7:30 AM EDT
VAYA Pharma Generated Record Net Revenues of $3.4 Million
GAAP Diluted EPS Impacted by Decline in the Krill Oil Revenues
Two U.S. Based Multinationals and Other Large Manufacturers Launched Infant Formula Containing INFAT® at CBME China Â
MIGDAL HA'EMEQ, Israel, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today reported financial results for the second quarter ended June 30, 2016.
... More
